We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer. Every day, we help improve the health of millions of people around the world by discovering, developing and manufacturing innovative medicines, vaccines and consumer healthcare products. We have a global presence across more than 100 countries which allows us to make a real contribution to the health and wellbeing of people all around the world.
We deliver our long-term priorities of Innovation, Performance and Trust through each of our three businesses which discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.
Our approach to Pharmaceutical Research and Development (R&D) focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. It will help us to accelerate the pace at which we develop and deliver transformational medicines, prioritising those molecules with a higher probability of success and terminating less promising programmes. It also enables us to increase our focus on specialty medicines in areas such as oncology.
In our Vaccines business, we balance our focus on a robust pipeline with the active life-cycle management of our existing vaccines, seeking to protect more people through expanding indications and delivering our vaccines to new geographies. Our Innovation ambition is to lead the industry by disrupting the discovery, development and manufacturing of vaccines. We will focus on accelerating key assets in our pipeline and looking at innovative technologies so that we can unlock potential in emerging fields. Using our industry-leading science, we will accelerate the delivery of our most promising assets to serve the greatest unmet medical need. We want to change the world with our science.
Our Consumer Healthcare R&D organisation develops products in five categories: Oral Health, Pain Relief, Respiratory, Nutrition and Gastrointestinal and Skin Health. Our focus is on building a strong, competitive pipeline of consumer-led, science-based innovation. On 1 August 2019 we announced that we'd completed our transaction with Pfizer to combine our consumer healthcare businesses into a new world-leading Consumer Healthcare Joint Venture. Within three years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company.
